Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

(2016) N. S. Raje et al.   CLINICAL CANCER RESEARCH

Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma

(2015) A. McBride et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

(2015) Simon J. Harrison et al.   AMERICAN JOURNAL OF HEMATOLOGY

Myeloma today: Disease definitions and treatment advances

(2015) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

An Enhanced Pre- and Postnatal Development Study in Cynomolgus Monkeys with Tabalumab: A Human IgG4 Monoclonal Antibody

(2015) William J. Breslin et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

Ixazomib for the treatment of multiple myeloma

(2015) Massimo Gentile et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

An update on the use of lenalidomide for the treatment of multiple myeloma

(2015) Flora Zagouri et al.   EXPERT OPINION ON PHARMACOTHERAPY

Lenalidomide in multiple myeloma

(2015) Young Kim et al.   Expert Review of Anticancer Therapy

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

(2015) J. G. Berdeja et al.   HAEMATOLOGICA

Targeting B-cell maturation antigen in multiple myeloma

(2015) Yu-Tzu Tai et al.   Immunotherapy

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

The European Medicines Agency Review of Pomalidomide in Combination With Low-Dose Dexamethasone for the Treatment of Adult Patients With Multiple Myeloma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

(2015) Z. Hanaizi et al.   ONCOLOGIST

Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma

(2015) Antonio Palumbo et al.   Expert Review of Hematology

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

(2015) S K Kumar et al.   Blood Cancer Journal

B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?

(2015) P J Hengeveld et al.   Blood Cancer Journal

Multiple Myeloma Gets Three New Drugs

(2015)   Cancer Discovery

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

(2015) J. G. Berdeja et al.   HAEMATOLOGICA

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

Current strategies for treatment of relapsed/refractory multiple myeloma

(2014) Jacob P Laubach et al.   Expert Review of Hematology

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

(2013) P. G. Richardson et al.   BLOOD

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

(2013) R. O. Carpenter et al.   CLINICAL CANCER RESEARCH

Evaluation of TNF superfamily molecules in multiple myeloma patients: Correlation with biological and clinical features

(2013) Dorota Lemancewicz et al.   LEUKEMIA RESEARCH

Relationship between Circulating BAFF Serum Levels with Proliferating Markers in Patients with Multiple Myeloma

(2013) Michael G. Alexandrakis et al.   Biomed Research International

B cell-activating factor: its clinical significance in multiple myeloma patients

(2012) M. Fragioudaki et al.   ANNALS OF HEMATOLOGY

Phase I Study of Atacicept in Relapsed/Refractory Multiple Myeloma (MM) and Waldenström's Macroglobulinemia

(2012) Jean-François Rossi   Clinical Lymphoma Myeloma & Leukemia

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules

(2012) Marina Bolzoni et al.   EXPERIMENTAL HEMATOLOGY

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

(2012) Andrzej J. Jakubowiak et al.   JOURNAL OF CLINICAL ONCOLOGY

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

(2008) A. A. Argyriou et al.   BLOOD